Palbociclib
Category: CancerPalbociclib Overview
Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.[1][2] Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy.[3] Contents 1 Mechanism of action 2 Administration 3 Approvals and indications 3.1 HR+ breast cancer 4 Adverse effects 5 ...
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Palbociclib
Recent Palbociclib Forums:
Be the first to start a discussion about this drug.Possible Dosages for this and Related Drugs:
Palbociclib
- Capsule: 100mg, 125mg, 75mg
- Tablet: 100mg, 125mg, 75mg
Other drugs which contain Palbociclib or a similar ingredient: (1 result)
- IBRANCE Palbociclib